Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-013365
Filing Date
2020-11-09
Accepted
2020-11-09 16:17:49
Documents
84
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q neos-20200930x10q.htm   iXBRL 10-Q 2885248
2 EX-10.1 neos-20200930xex10d1.htm EX-10.1 102709
3 EX-31.1 neos-20200930xex31d1.htm EX-31.1 12302
4 EX-31.2 neos-20200930xex31d2.htm EX-31.2 12842
5 EX-32.1 neos-20200930xex32d1.htm EX-32.1 8826
6 GRAPHIC neos-20200930x10q001.jpg GRAPHIC 633
  Complete submission text file 0001558370-20-013365.txt   11136175

Data Files

Seq Description Document Type Size
7 EX-101.SCH neos-20200930.xsd EX-101.SCH 73078
8 EX-101.CAL neos-20200930_cal.xml EX-101.CAL 74184
9 EX-101.DEF neos-20200930_def.xml EX-101.DEF 316835
10 EX-101.LAB neos-20200930_lab.xml EX-101.LAB 717935
11 EX-101.PRE neos-20200930_pre.xml EX-101.PRE 565388
12 EXTRACTED XBRL INSTANCE DOCUMENT neos-20200930x10q_htm.xml XML 1872117
Mailing Address 2940 N. HIGHWAY 360 SUITE 400 GRAND PRAIRIE TX 75050
Business Address 2940 N. HIGHWAY 360 SUITE 400 GRAND PRAIRIE TX 75050 972.408.1360
Neos Therapeutics, Inc. (Filer) CIK: 0001467652 (see all company filings)

EIN.: 270395455 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37508 | Film No.: 201297920
SIC: 2834 Pharmaceutical Preparations